NUCIEN PHARMA(SH:688189) Xin Lang Cai Jing·2025-11-12 02:18Core Viewpoint - Nanjing Pharmaceutical's stock price has shown significant volatility, with a year-to-date increase of 51.38% but a recent decline in the last 60 days by 27.90% [2][3] Company Overview - Nanjing Pharmaceutical, established on December 27, 2006, and listed on March 26, 2020, focuses on the research, production, and sales of antiviral and infectious disease treatment drugs, as well as medications for major diseases like cardiovascular diseases and diabetes [2] - The company operates entirely in the chemical drug formulation sector, with 100% of its revenue derived from this area [2] Financial Performance - For the period from January to September 2025, Nanjing Pharmaceutical reported a revenue of 83.15 million yuan, a year-on-year decrease of 66.89%, and a net profit attributable to shareholders of -68.63 million yuan, reflecting a 19.96% decline [3] - The company has not distributed any dividends in the last three years, with a total payout of 40.74 million yuan since its A-share listing [4] Shareholder Information - As of September 30, 2025, the number of shareholders increased by 49.13% to 14,100, while the average number of tradable shares per person decreased by 32.95% to 19,441 shares [3] - New institutional shareholders include several funds from GF Fund Management, indicating a shift in the shareholder base [4] Market Activity - Nanjing Pharmaceutical's stock experienced a net outflow of 529,500 yuan in major funds, with significant buying and selling activity observed [1] - The stock has appeared on the "Dragon and Tiger List" seven times this year, indicating notable trading activity [2]